Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer
immune checkpoint inhibitor combined with recombinant human endostatin can improve the 3-month OS rate of leptomeningeal metastasis of lung cancer, and the combination is safe
Leptomeningeal Metastasis|Immune Checkpoint Inhibitor|Endostatin
DRUG: Camrelizumab or envafolimab
3-month overall survival rate, The 3-month survival rate after treatment, 3 month|safty, Adverse events related to treatment, 2 years
iPFS, Intracranial progression-free survival, 2 years|extracranial PFS, extracranial progression-free survival, 2 years|DCR, disease control rate, 2 years
We will recruit 20 patients with leptomeningeal metastases from lung cancer.